Regulator-mandated study finds no link between semaglutide use and pancreatic cancer

by European Association for the Study of Diabetes

edited by Sadie Harley, reviewed by Andrew Zinin

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

proofread

The GIST Add as preferred source

New research presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, found no link between semaglutide use and pancreatic cancer in nationwide registry data from Denmark, Sweden and Norway. The regulator-mandated post-authorization study was presented by Anton Pottegård, a professor at the University of Southern Denmark in Odense, and colleagues.

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) indicated for the treatment of type 2 diabetes mellitus (T2DM) and weight management. A risk of pancreatic cancer has been hypothesized for incretin-mimetic antidiabetic drugs, including GLP-1RAs.

The hypothesis arose from early safety signals in adverse event reporting systems and preclinical studies in rodents showing cellular changes in pancreatic tissue. Because GLP-1 medications stimulate the pancreas and were occasionally linked to acute pancreatitis in early case reports, researchers also questioned whether chronic inflammation could eventually elevate cancer risk.

As part of the original approval process for semaglutide (Wegovy/Ozempic), regulators requested a post-authorization safety study to estimate the risk of pancreatic cancer associated with semaglutide use compared with other non-incretin drugs used to treat T2DM.

Using nationwide health registries from Denmark, Sweden and Norway, the researchers conducted an active-comparator, new-user cohort study examining the risk of pancreatic cancer in new users of semaglutide for T2DM versus matched new users of non-incretin antidiabetic drugs (sulfonylureas, SGLT-2 inhibitors, or insulin). Eligible patients started semaglutide or an active comparator and filled at least two prescriptions within the first year. Follow-up began one year after treatment started.

The primary outcome was a new diagnosis of pancreatic cancer. Country-specific hazard ratios (HRs) and incidence rate differences (IRDs) were estimated and pooled across countries using a fixed-effects meta-analysis. The researchers performed extensive sensitivity and supplementary analyses to assess the robustness of the findings.

In total, 97,464 semaglutide users were included, with patient characteristics well balanced against those of a matched control cohort. Among semaglutide users, median age ranged from 59 to 62 years, with mean follow-up after the 1-year lag period of 1.40–1.85 years.

A total of 131 pancreatic cancer cases occurred among semaglutide users and 123 among active comparator users (across 167,399 and 140,306 person-years of follow-up, respectively). Incidence rates were similar between groups across countries, ranging from 0.64 to 0.91 per 1,000 people per year among semaglutide users and 0.80 to 0.98 among active comparator users.

Semaglutide use was not associated with an increased risk of pancreatic cancer compared with active comparators in any country (hazard ratio 1.00 [95% confidence interval 0.66–1.51] in Denmark, 0.82 [95% CI 0.56–1.22] in Sweden, and 0.91 [95% CI 0.55–1.51] in Norway). Pooled estimates also showed no increased risk (pooled HR 0.91 [95% CI 0.71–1.16] and incidence rate difference [IRD, or absolute risk] −0.10 [95% CI −0.31 to 0.10] per 1,000 person-years).

No cumulative dose-response or dose-duration effects were observed (pooled HR for high dose: 0.74 [95% CI 0.40–1.40]; pooled HR for long duration: 0.79 [95% CI 0.37–1.69]). Sensitivity and supplementary analyses consistently showed no increased risk.

Pottegård concludes, "This comprehensive study, using nationwide registry data from three countries, found no increased risk of pancreatic cancer with use of semaglutide as compared to use of other glucose-lowering drugs used at a similar stage as semaglutide in the treatment of T2DM.

"This conclusion was supported by the absence of a cumulative dose-response or dose-duration effect, consistent findings in the individual countries and in a wide range of supplementary and sensitivity analyses. These findings also align with current external evidence and thus further strengthen the evidence that semaglutide does not increase the risk of pancreatic cancer."

Key medical concepts

Pancreatic CancerSemaglutideDiabetes Type 2GLP-1 Receptor Agonist [EPC]

Clinical categories

EndocrinologyOncologyWeight management Provided by European Association for the Study of Diabetes Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Regulator-mandated study finds no link between semaglutide use and pancreatic cancer (2026, September 28) retrieved 29 September 2026 from https://medicalxpress.com/news/2026-09-mandated-link-semaglutide-pancreatic-cancer.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.